Stockscreener 앱 받기
11.69
2.26%
-0.27
시간 외 거래:
11.69
Cullinan Therapeutics Inc 주식(CGEM)의 최신 뉴스
CGEM: 2026 will deliver key data for T cell engagers in autoimmune and AML, driving major portfolio catalysts - TradingView
Retail Trends: Whats the profit margin of Cullinan Therapeutics IncProduct Launch & Intraday High Probability Alerts - baoquankhu1.vn
Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Guggenheim Upgrades Cullinan Therapeutics (NASDAQ:CGEM) to Strong-Buy - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month HighTime to Buy? - MarketBeat
Guggenheim Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on CGEM with a 'Buy' Rating | CGEM Stock News - GuruFocus
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target By Investing.com - Investing.com UK
Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers - Seeking Alpha
What is Cullinan Therapeutics Inc.’s valuation compared to sectorPortfolio Return Summary & Advanced Technical Analysis Signals - mfd.ru
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? - Yahoo Finance
Aug Patterns: What drives Cullinan Therapeutics Incs stock price2025 Pullback Review & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Levels Update: What drives Cullinan Therapeutics Incs stock priceMarket Weekly Review & Low Risk High Reward Ideas - baoquankhu1.vn
Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Cullinan Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $49,200.00 in Stock - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth? - Sahm
Cullinan Therapeutics (NASDAQ:CGEM) Cut to "Sell" at Wall Street Zen - MarketBeat
Stocks to watch: Cullinan Therapeutics sees RS rating jump to 91 - MSN
Insider Sell: Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics Inc (CGEM) - GuruFocus
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Gainers Report: Can Cullinan Therapeutics Inc outperform under higher oil prices2025 Support & Resistance & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength - Yahoo Finance
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 10.6%Here's Why - MarketBeat
History Review: What is the Moat Score of Cullinan Therapeutics IncIPO Watch & Verified Momentum Stock Alerts - baoquankhu1.vn
Will Cullinan Therapeutics Inc benefit from AI trends2025 Market WrapUp & Risk Controlled Swing Alerts - baoquankhu1.vn
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 6.2%Here's What Happened - MarketBeat
Published on: 2026-01-11 22:17:06 - ulpravda.ru
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics provides corporate update, anticipated 2026 milestones - Yahoo Finance
Market Fear: Will Cullinan Therapeutics Inc. stock split again soonWeekly Stock Report & Real-Time Volume Triggers - ulpravda.ru
Will Cullinan Therapeutics Inc. stock split again soonProfit Target & Weekly Return Optimization Alerts - ulpravda.ru
How strong is Cullinan Therapeutics Inc. stock balance sheetQuarterly Trade Review & Reliable Breakout Stock Forecasts - ulpravda.ru
Today's Analyst Ratings Update: CGEM Price Target Raised to $27 - GuruFocus
Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook - TipRanks
Cullinan Therapeutics (CGEM) Outlines Key Developments for 2026 - GuruFocus
Cullinan Therapeutics plans data readouts for key autoimmune programs By Investing.com - Investing.com Australia
Cullinan Therapeutics plans data readouts for key autoimmune programs - Investing.com India
Cullinan Therapeutics Outlines 2026 Milestones for CLN-978 and CLN-049 Programs, NDA Submission for Zipalertinib - Quiver Quantitative
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - Chartmill
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 9.5%Here's Why - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (NQ:CGEM) - FinancialContent
1.24%
0.19%
자본화:
|
볼륨(24시간):